and is then cleaved into an active carbossi-terminal peptide and an amino-terminal fragment. 5 NPs exert their functions by binding to the guanylyl cyclaselinked NP receptors: type A (NPR-A) and type B (NPR-B). 6 By stimulating cyclic guanosine monophosphate (cGMP) as a second intracellular messenger, NPR-A mediates all the known biological effects of ANP and BNP. In contrast, CNP preferentially binds to NPR-B.
NPs play an important role in the regulation of electrolytes and water balance through their diuretic and natriuretic effects. They also inhibit the renin-angiotensin-aldosterone system and regulate the permeability of systemic vasculature. In addition, they inhibit the activity of the sympathetic nervous system. In this regard, ANP interacts with the baroreflex control of the circulation by modulating both the arterial and cardiopulmonary baroreceptor-mediated control of sympathetic outflow. 7 As a result, heart rate and blood pressure decrease. In addition, a negative inotropic effect of ANP has been described in normal left ventricular (LV) myocytes, but not in hypertrophied myocytes. 8 In this manner, through their renal, cardiovascular, and neural actions, NPs play a major role in contributing to the regulation of cardiac hemodynamics and performance. In fact, NPs, once secreted in response to myocardial stretch, produce important systemic actions that antagonize volume overload, thereby constituting an important physiological protective system in heart failure, and a potential therapeutic tool for use in this clinical condition. 9 In particular, the sympathoinhibitory Natriuretic Peptides and Cardiovascular Functions STATE OF THE ART effects of NPs have proved to be a major advantage in combating congestive heart failure. 10 New evidence suggests that NPs play additional beneficial roles in the cardiovascular system, mainly through their autocrine and/or paracrine actions. ANP modulates cellular growth and proliferation of endothelial and smooth muscle cells in the vascular wall, 11 wherein it also exerts anti-inflammatory properties. 12 An inhibitory effect on atherosclerosis in vivo has been documented. 13 In addition, an antihypertrophic role for ANP within the myocardium has been clearly demonstrated. 14 This review focuses on the major new findings relating to the cardiovascular effects of NPs, with particular emphasis on ANP. It examines the role of these important cardiovascular hormones in mediating cardiovascular diseases, and discusses their current clinical relevance and their potential therapeutic applications.
NPs aNd blood Pressure
Since its discovery in 1981, 1 several studies have investigated the role of ANP as a pathophysiological determinant of hypertension. In this regard, it was shown that the infusion of high doses of α-ANP into normal volunteers produces a significant reduction in mean blood pressure, associated with a slight increase in heart rate and the expected marked increase in urinary excretion of sodium, chloride, and calcium. 15 Subsequently additional important evidence has been provided by molecular genetic studies to support the close link between ANP and blood pressure control. In particular, genetically reduced ANP leads to salt-sensitive hypertension 16 whereas genetically increased ANP leads to hypotension in mice. 17 More recently, through a combined cross-sectional and longitudinal approach, we have obtained the first evidence of the effect of an ANP gene promoter variant (associated with significantly decreased pro-ANP plasma levels) on increased susceptibility to early development of hypertension and its vascular complications in humans. 18 Both pathophysiological and molecular genetics studies consistently show that changes in the levels of circulating ANP are inversely related to changes in blood pressure, i.e., lowering of ANP levels raises blood pressure, and increase in ANP levels lowers blood pressure.
In contrast, both BNP and CNP behave as weaker determinants of blood pressure levels. 19, 20 On the basis of this assumption, it appears reasonable to propose ANP as an appropriate agent in therapeutic strategies to control hypertension. In fact, the use of ANP as a therapeutic agent has been explored extensively. Both short-and long-term infusions of ANP have been tested in essential hypertension as well as in secondary forms of hypertension, producing reduction in blood pressure, along with natriuresis and diuresis. 21, 22 However, a strategy that calls for long-term infusion of ANP does not represent a practical solution for the treatment of patients with hypertension.
With the development of molecular genetics, the use of gene transfer and gene therapy strategies for long-term control of hypertension have become feasible, holding out the promise of their possible therapeutic application for achieving effective and prolonged control of high blood pressure. 23 A single intravenous injection of naked human ANP DNA construct (fused to the rous sarcoma virus 3′-long-terminal repeat) produced a sustained reduction in blood pressure in young, but not in adult, spontaneously hypertensive rats. 24 The preventive effect on development of hypertension was achieved without causing any apparent side-effect or immune response.
More recently, in order to overcome the problem arising from the need to ensure an adequately controlled, long-term ANP gene expression, gene therapy involving ANP has been performed with a helper-dependent adenoviral vector carrying the mifepristone-inducible gene-regulatory system for controlling in vivo ANP expression. 25 Achievement of a sustained ANP expression (>120 days) was associated with: a decrease in systolic blood pressure, an increase in urinary cGMP excretion, and a decrease in heart weight. These findings provide the basis for evaluating the effectiveness of ANP gene delivery as a strategy for treating essential hypertension in human subjects. Additional studies are obviously required in order to address this issue thoroughly, and to move from animal experiments to the stage of clinical trials.
An alternative approach is represented by a strategy based on pharmacologically increased circulating ANP levels. For this purpose, a new class of drugs was developed, i.e., inhibitors of neutral endopeptidase (NEP). By simultaneously blocking NEP and angiotensin-converting enzyme, these compounds (i.e., omapatrilat) lead to reduced degradation of NP and bradykinin, with a concomitant inhibition of angiotensin II generation. 26 With this approach, the achievement of higher levels of NP, together with other mechanisms, is expected to effectively control blood pressure in subjects with hypertension. In fact, some studies have shown that the hypotensive effect produced by NEP inhibitors is greater than that achieved by angiotensinconverting enzyme inhibitors alone. 27, 28 However, a threefold greater risk of angioedema, particularly in black individuals, 28 has raised concerns of safety and prevented the introduction of NEP inhibitors into clinical practice.
NP aNd cardiac remodeliNg
Increases in cardiac ANP expression and in ANP plasma levels have been extensively used as markers of left ventricular hypertrophy (LVH). 29 Both ANP and BNP have been described as markers of right ventricular hypertrophy. 30 The first observation of the active role played by ANP in modulating cardiac mass 
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derives from animal experiments. In fact, knockout of ANP gene in the mouse led to an increase in cardiac mass. 16 This phenotype was unrelated to the parallel increase in blood pressure (a form of salt-sensitive hypertension). In another study, overexpression of ANP in the mouse caused decrease in heart size. 17 In addition, genetic manipulation of the NPR-A gene has provided further substantial support to the concept of ANP as an active modulator of cardiac hypertrophy. In fact it has been shown that both the systemic and the selective intracardiac knockout of NPR-A were associated with an increasein LVH. 31, 32 Conversely, overproduction of NPR-A in the heart reduced the size of cardiac myocytes. 33 Several signaling pathways serve as agonists or antagonists to hypertrophic growth of cardiac myocytes. It is likely that ANP inhibits a variety of hypertrophic cellular signaling through the stimulation of NPR-A and the downstream production of cGMP and PKG (protein kinase type I). Several studies have been performed in attempting to explore this issue. In vitro studies have shown that ANP exerts its direct inhibitory effect on growth, at least partly through the induction of MAPK phosphatase-1, 34 a dual serine/threonine and tyrosine phosphatase that specifically inactivates MAPK family members such as ERKs, JNK, and p38MAPKs. The latter proteins are involved in cell proliferation and hypertrophy. 35 It has also been reported that ANP inhibits the norepinephrine-induced growth of cardiac myocytes through a cGMPmediated inhibition of norepinephrine-stimulated Ca 2+ influx. 36 Further, inhibition of the calcineurin-nuclear factor of activated T cells signaling pathway has been demonstrated in NPR-A deficient mice 37 and in hypertensive eNOS (hypertensive endothelial nitric oxide synthetase deficient mice) mice. 38 Other mechanisms involve inhibition of the production of reactive oxygen species (an emerging growth-signaling factor in cardiomyocytes) through inhibition of their major source, reduced nicotinamide adenine dinucleotide phosphate dehydrogenase oxidase. 39 The first demonstration of a direct genetic association between ANP and cardiac mass in humans was recently obtained by our group in a cohort of patients affected by essential hypertension. 40 In this study, a promoter ANP gene variant that is associated with significantly reduced circulating N-terminal pro-ANP levels was seen to be associated with increased cardiac mass, independent from all anthropometric and clinical parameters as well as from pharmacological treatments. In the same study, an allelic variant of the NPR-A gene, likely to be the one responsible of receptor dysfunction, was also associated with LVH, thereby confirming earlier evidence obtained with a functional deletion mutation of the NPR-A gene 5′-flanking region. 41 It is interesting to note that similar findings with the ANP gene were more recently reported in a large cohort of patients with hypertension, with and without LVH. 42 An additional indirect evidence of the antihypertrophic role of ANP in humans comes from a study performed in patients affected by essential hypertension along with metabolic syndrome. 43 In this latter condition the incidence of LVH is significantly higher. 44 Moreover, in individuals with metabolic syndrome 43, 45 and in those with obesity, 46 the levels of NP are significantly lower for yet unknown reasons. Interestingly, we found that circulating ANP levels are inversely related to cardiac mass to a significant extent, and that this inverse relationship remains significant even after adjusting for relevant clinical variables. 43 On the basis of experimental and clinical evidence, it is now generally accepted that the ANP/NPR-A system behaves as a counter-regulatory, "friendly" mechanism toward hypertrophic growth responses within the heart. 14 The inadequate response of this system (because of genetic, metabolic, or other factors) favors cardiac hypertrophy and, in the long term, the secondary dilation of the heart and the development of heart failure.
The existence of autocrine and paracrine cardiac actions of endogenous ANP has recently received strong support by the first visualization of high-affinity ANP-binding sites in the human heart. 47 In this work, expression of NPR-A receptors was demonstrated for the first time in cardiomyocytes and coronary vascular smooth muscle cells. Moreover, a diseasedependent change in NPR-A density in the myocardium was shown, with a significant downregulation in patients affected by severe ischemic heart disease, idiopathic dilated cardiomyopathy, and heart failure. It is evident, therefore, that reduction in NPR-A function and in NP response in all these conditions can only favor propensity toward hypertrophy and fibrosis.
Therefore any future therapeutic approach should seek to maintain the ANP levels at least within the physiological range, and certainly well above the low levels that are known to contribute to the development of LVH. In this regard, both ANP gene therapy and blockade of the ANP breakdown may represent valuable and promising approaches, if the maintenance of physiological levels of ANP can be ensured. In fact, evidence regarding cardiac mass modulation under both ANP gene therapy and NEP inhibition is already available, but only in the presence of therapeutically induced high ANP levels. It has been reported that mice receiving ANP at supraphysiological doses by gene therapy showed a remarkable reduction of the heart-weight/body-weight ratio and, when examined by echocardiography, they showed a decrease in cardiac function (decrease in peak aortic flow velocity, mean and peak aortic flow acceleration, and stroke volume). 25 These effects, that likely represent the results of both reduction of excessive load and the direct antihypertrophic effect of high ANP levels, need to be verified under physiological ANP concentrations.
On the other hand, the evidence so far available with the use of NEP inhibitors is not easy to relate solely to the Natriuretic Peptides and Cardiovascular Functions STATE OF THE ART natriuretic peptide system alone, because the findings represent the net effect a complex hormonal modulation (blockade of the renin-angiotensin-aldosterone system, increase of natriuretic peptides, bradykinin, adrenomedullin, and substance P). In particular, vasopeptidase inhibition produced attenuation of atrial and ventricular dilation and of ventricular hypertrophy in failing hearts, thereby indicating preload and afterload reductions under this type of therapy. 48 Apart from the hemodynamic effects, a direct inhibition of collagen synthesis in cardiac fibroblasts has been demonstrated in vitro under exposure to vasopeptidase inhibitors. 48 Further, in an experimental model of cardiomyopathy, a superior effect on improvement of cardiac geometry and survival was observed with NEP inhibition as compared to the angiotensin-converting enzyme inhibition alone. 49 However, no difference was found as regards improvement of ventricular size and function in a study of patients with hypertension treated with either NEP inhibitor or angiotensin-converting enzyme inhibitor. 50 Another interesting aspect that has been explored is the ability of ANP to prevent LV dilation and remodeling after primary coronary angioplasty in patients with acute myocardial infarction (MI). 51 Patients received either ANP infusion or isosorbide dinitrate administration immediately after primary coronary angioplasty. The outcome after ANP infusion was superior to that obtained with isosorbide dinitrate. This finding is probably attributable to an increase in the myocardial uptake of norepinephrine by blockade of the renin-angiotensin-aldosterone system. Moreover, through stimulation of ATP-sensitive potassium channel activity, ANP can favor an ischemic preconditioning effect during ischemia reperfusion and, by so doing, exert a cardioprotective effect against prolonged ischemia.
Recent studies have suggested an important role in cardiac remodeling for CNP as well. In fact, it has been shown that CNP exerts antihypertrophic effects (that are even more potent than those exerted by ANP) on cardiac myocytes in vitro. 52 Interestingly, CNP acts also as an efficient antiremodeling agent after acute MI. In fact, serial infusions of CNP in rats after acute MI were associated with reduction in LV dilatation, increase in systolic and diastolic performance, and reduction in ventricular fibrosis. 53 These studies underline the therapeutic potential of NPs in the treatment of acute MI, and their beneficial effects on morbidity and mortality in post-MI patients.
NP aNd vascular remodeliNg
ANP induces potent and efficacious endothelium-independent vasodilation in both small, resistance arteries and large, conduit arteries. It also modulates the tone of smaller veins and venules. As a consequence, a significant reduction of preload and afterload takes place in the presence of a functional ANP/ NPR-A system. 1 Recently, in a relatively healthy sample population with a low prevalence of cardiovascular diseases, the level of N-terminal pro-ANP was found to be positively related to conduit brachial artery function, as assessed by flow-mediated dilation. 54 N-terminal pro-ANP was also inversely related to baseline mean flow velocity. Interestingly, among seven biomarkers (including BNP, renin, aldosterone, PRC, PAI-1, and urine albumin-creatinine ratio) evaluated in parallel in the same study sample, N-terminal pro-ANP turned out to be the strongest correlate of brachial artery endothelial function. 54 Therefore, through its potent vasodilation action, ANP appears to be the strongest contributor to endothelial function in the general population.
In human coronary arterial endothelial cells and in human umbilical vein endothelial cells, a low dose of ANP (10 −11 mol/l) induced an increase in cell numbers and [ 3 H]thymidine incorporation (a marker of DNA synthesis), and an increase in cell migration. 11 The effects were mediated by an increase in the expression of cGK and, subsequently, Akt and ERK1/2 (p44/42 MAPK) pathways. It is evident that physiological concentrations of ANP promote endothelial regeneration and could therefore be useful in the regeneration of endothelial cells after injury in atherosclerosis. On the other hand, supraphysiological levels of ANP exert an opposite effect. In fact, they reduce endothelial cell regeneration, DNA synthesis, and cell migration. 11 ANP is therefore an interesting agent for modulating angiogenesis, and particularly for inducing endothelial regeneration after vascular injury. However, studies exploring this therapeutic potential of ANP have not been reported to date.
Consistent with the negative effects on cell survival after exposure to high levels of ANP, an association between elevated NP levels and increase in mortality rates has been reported in patients with heart failure, acute coronary syndrome, or stroke, and even in the general population, in the context of stratification according to perceived cardiovascular risk. [55] [56] [57] With regard to stroke, high NP levels have been shown to predict poststroke mortality. 56 Apart from the toxic vascular effects exerted by high plasma levels, the possible pathological relevance of a structurally mutant ANP peptide has been recently highlighted. In fact, the presence of a structurally different ANP has been shown to be associated with a higher incidence of cerebrovascular disease in a rat model and in different human populations. [58] [59] [60] In addition, an increased risk of MI has been reported in subjects carrying a coding mutation of the peptide. 61 A recent study has highlighted a significant association between ANP gene mutations and cardiovascular outcome after pharmacological therapy in patients with hypertension. 62 Downloaded from https://academic.oup.com/ajh/article-abstract/21/7/733/83976 by guest on 01 January 2019
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CNP, in turn, regulates the vascular tone, particularly in small, resistance arteries. It exerts a potent endotheliumindependent vasodilatory effect, acting mainly as an endothelium-derived hyperpolarizing factor. 63 Experimental evidence supports a role for CNP as a vascular antiremodeling agent. In fact, CNP inhibits platelet-derived growth factor-induced vascular smooth muscle cell growth 64 and prevents intimal thickening after vascular injury. 65 
NPs aNd metabolism
NPs exert potent lipolytic effects in isolated human fat cells as well as in adipocytes in vivo through cGMP-mediated phosphorylation. 66, 67 Moreover, when administered intravenously, ANP favors lipolysis (breakdown of triglycerides into nonesterified fatty acids and glycerol) through activation of hormonesensitive lipase in human fat cells. 68 This effect has been shown both in vitro and in vivo. 66, 68 Other studies have shown that ANP can inhibit the proliferation of human visceral preadipocytes. 69 Therefore a reduced NP signaling could promote lipid accumulation in adipose tissue and skeletal muscle, and this could lead to an increased susceptibility to developing visceral adiposity which is associated with dyslipidemia, insulin resistance, and increased cardiovascular risk. 70 On the other hand, it has also been suggested that the high ANP levels observed in heart failure may contribute to the cardiac cachexia seen in these patients. 68 With regard to insulin resistance, an inverse association of NP with both plasma glucose and insulin levels has been described earlier. 71 That is, low NP levels could potentially predispose to insulin resistance through various mechanisms, such as greater activation of the renin-angiotensin-aldosterone system (resulting in enhanced oxidative stress), 72 increased systemic inflammation, 12 and interference with insulinstimulated glucose transport. 73 It has also been demonstrated that ANP inhibits glucagon secretion through its direct effect on pancreatic islets. 74 Obese individuals have lower NP levels as compared to lean subjects. 46 In fact, it has been suggested that low peptide levels could contribute to the increased cardiovascular risk for obese individuals in terms of fluid retention, hypertension, and heart failure. Recent studies have demonstrated that the levels of both BNP and ANP are also significantly decreased in patients affected by metabolic syndrome (a cluster of obesity, hyperlipidemia, and hypertension). 43, 45 The reasons underlying the reduction in NP levels in persons with obesity and/or metabolic syndrome are still unclear. They may include a decreased cardiac synthesis and an increased clearance by the adipose tissue (where the clearance receptor NPR-C is strongly expressed 75 ). Indeed, given that the N-terminal fragments of ANP and BNP, which are not cleared by NPR-C, tend to be lower in obese subjects, 46 it may be reasonable to hypothesize a reduced cardiac secretion of NP as being the main pathogenetic mechanism.
Interestingly, the lower N-terminal ANP levels found in patients affected by metabolic syndrome are inversely related to LVH, independent from all clinical and anthropometric variables. 43 They are also inversely associated with the metabolic risk factors, with the components of the metabolic syndrome, and with the metabolic syndrome itself, as recently reported in the Framingham population. 71 It is possible that, whatever the cause of lower NP levels in obesity and metabolic syndrome, the lower peptide levels contribute to the susceptibility of obese subjects to developing hypertension, LVH, and adverse cardiovascular events.
NPs aNd iNflammatioN/fibrosis
NPs exert several anti-inflammatory and antifibrotic effects that have been demonstrated mainly in vitro. In particular, ANP directly reduces the production of tumor necrosis factor-α by macrophages. 12, 76 It also inhibits, through lipolysis-derived products, the secretion of a wide range of adipose tissue-secreted cytokines, chemokines, and adipokines, which are involved in leucocyte recruitment, and could predispose to insulin resistance. 12 Moreover, ANP can interfere with the proinflammatory effects of tumor necrosis factor-α, such as the expression of endothelium adhesion molecules (intercellular cell adhesion molecule, vascular cell adhesion molecule, and monocyte chemotactic protein-1), through activation of nuclear factor-κB. 77 ANP can directly inhibit the actions of cyclooxygenase-2 (ref. 78 ) and of inducible nitric oxide synthase. 79 In addition, ANP reduces the hypoxia-mediated adhesion of neutrophils to endothelial cells. 80 In fact, NEP inhibitors significantly enhance the inhibitory effect of ANP on the interaction between neutrophils and the endothelium. 81 CNP also inhibits the expression of endothelium adhesion molecules. 82 NPs exert important effects on cardiac fibroblasts by reducing DNA synthesis, in particular, collagen synthesis. This effect of NPs is blocked by NEP inhibitors. 83 In particular, ANP blocks the tumor growth factor-β-induced myofibroblast transformation, proliferation, and collagen synthesis in mouse cardiac fibroblasts. 84 BNP inhibits the profibrotic action of tumor growth factor-β. 85 CNP inhibits the proliferation and collagen synthesis in cardiac fibroblasts. 86 Both BNP and GC-A knockout mice show severe myocardial fibrosis and increased tumor growth factor-β1 expression. 19, 32 Further, we have recently demonstrated that N-terminal ANP levels are inversely related to tumor growth factor-β levels in hypertensive patients with metabolic syndrome, thereby confirming the earlier experimental evidence, and suggesting that this interaction could contribute to the antihypertrophic effects of ANP in hypertension in humans. 43, 87 Natriuretic Peptides and Cardiovascular Functions
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NPs aNd lv dysfuNctioN
A state of acute heart failure is associated with very high levels of NPs. 9, 88 In particular, BNP has been extensively investigated as a marker of LV dysfunction. Wherever LV dysfunction is present, BNP levels are always proportionally elevated. In fact, an evaluation of the use of BNP levels for identifying asymptomatic individuals with poor ventricular function has led to significant results. BNP levels also increase as a consequence of right heart dysfunction caused by lung diseases of different etiologies. 89 As a consequence, the clinical relevance of BNP has been particularly highlighted in the context of heart failure, wherein its levels reflect the severity of LV dysfunction. In addition, BNP provides important prognostic information about future outcome and risk of death in patients affected by congestive heart failure. 90 Large epidemiological studies have shown that, in the presence of coronary artery disease and LV dysfunction, BNP levels represent the strongest predictor of future adverse cardiovascular events. 91 It is interesting to note that the application of the predictive role of BNP levels has been extended to evaluating postoperative outcome in patients undergoing electrophysiological procedures (such as a defibrillator implantation) or cardiac surgery. In fact, BNP can predict future appropriate defibrillator therapies in cardiomyopathy patients; it also predicts cardiac resynchronization therapy response at 6 months and postoperative outcome after coronary valvular disease surgery. 89 On the basis of this body of evidence, it is reasonable to monitor BNP levels in patients with LV dysfunction in order to evaluate the response to the treatments. In fact, this measurement can help in the management of patients and contribute to improved patient care and outcome.
With regard to CNP, it was also found to be higher in patients with heart failure, being correlated to pulmonary capillary wedge pressure, 92 and was associated with an increase in the levels of all the peptides that are usually elevated in congestive heart failure. 93 coNclusioNs NPs have revealed, over time, numerous cardiovascular functions beyond those that are strictly related to the control of blood pressure homeostasis. These include the promotion of cardiac and vascular health and the regulation of metabolism in adipose tissue. Whereas the control of blood pressure and electrolyte homeostasis represent the result of the role of NP as endocrine substances, the other effects are mainly because of their autocrine/paracrine functions.
As a consequence of their physiological relevance, NPs also have a significant impact on the etiopathogenesis and pathophysiology of cardiovascular diseases. With regard to ANP, both altered plasma levels and abnormal aminoacid sequences can cause derangements of ANP cardiovascular functions, thereby making ANP an important cardiovascular risk factor and a determinant of the outcome in patients with cardiovascular diseases (Figure 1) .
Interestingly, although ANP and BNP induce similar cardiovascular responses in the heart, blood vessels, and kidneys, and although they signal through the same NPR-A receptor, they seem to play different roles in the contribution to the cardiovascular risk. In fact, whereas BNP appears to be the most appropriate marker of LV dysfunction and an excellent predictor of deterioration in cardiac function, it behaves as a weaker determinant of blood pressure levels as compared to ANP; 19 it is not associated with endothelial function in the context of the general population; 54 and it acts as an antifibrotic rather than as an antihypertrophic agent in the myocardium. 19 Further, mutations of the BNP gene have not been described as being associated with an increased risk of developing cardiovascular disease.
The reasons underlying the different patterns of behavior of ANP and BNP in the pathogenesis of cardiovascular diseases certainly deserve further investigation. 
